Back to Results

A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma


Is this Study for You?

Let's Get Started!




Choroidal tumor must be no greater than 2.5 mm in height and 10 mm in width and show growth over 3 months to 2 years. Must be treatment naive with no other cancer or metastatic disease.

Type of Study



University of Colorado Hospital

Principal Investigator
Scott Oliver,  MD

Scott Oliver, MD

Study ID

Protocol Number: 20-1186

More information available at NCT04417530

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers